Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector

Cancer Research

Volumn 60, Issue 2, 2000, Pages 334-341

  Latham, James P F ^a   Searle, Peter F ^a   Mautner, Vivien ^a   James, Nicholas D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GREEN FLUORESCENT PROTEIN; KALLIKREIN; NITROREDUCTASE; PROSTATE SPECIFIC ANTIGEN; VIRUS VECTOR;

ARTICLE; ENHANCER REGION; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN ADENOVIRUS 2; HUMAN CELL; LEUKEMIA CELL LINE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN ANALYSIS; TISSUE SPECIFICITY; WESTERN BLOTTING;

ADENOVIRIDAE; ANDROGENS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL SURVIVAL; COLONIC NEOPLASMS; COLORING AGENTS; CYTOMEGALOVIRUS; ENHANCER ELEMENTS (GENETICS); GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; JURKAT CELLS; KINETICS; LUCIFERASES; LUMINESCENT PROTEINS; MALE; OXAZINES; POLYMERASE CHAIN REACTION; PRODRUGS; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; TISSUE KALLIKREINS; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; XANTHENES;

EID: 0034650401     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hakalahti, L., Vihko, P., Autio-Harmainen, H., Soini, Y., and Vihko, R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses in situ hybridisation and immunocytochemical stainings with monoclonal and bispecific antibodies. Int. J. Cancer, 55: 590-597, 1993.
2. Qiu, S. D., Young, C. Y., Bilhartz, D. L., Prescott, J. L., Farrow, G. M., He, W. W., and Tindall, D. J. In situ hybridization of prostate-specific antigen mRNA in human prostate. J. Urol., 144: 1550-1556, 1990.
3. Young, C. Y., Andrews, P. E., Montgomery, B. T., and Tindall, D. J. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry, 31: 818-824, 1992.
4. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., and Redwine, E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 317: 909-916, 1987.
5. Digby, M., Zhang, X. Y., and Richards, R. I. Human prostate specific antigen (PSA) gene: structure and linkage to the kallikrein-like gene, hGK-1. Nucleic Acids Res., 17: 2137, 1989.
6. Schedlich, L. J., Bennetts, B. H., and Morris, B. J. Primary structure of a human glandular kallikrein gene. DNA (NY), 6: 429-437, 1987.
7. Murtha, P., Tindall, D. J., and Young, C. Y. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry, 32: 6459-6464, 1993.
8. Young, C. Y., Montgomery, B. T., Andrews, P. E., Qui, S. D., Bilhartz, D. L., and Tindall, D. J. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res., 51: 3748-3752, 1991.
9. Chariesworth, M. C., Young, C. Y., Klee, G. G., Saedi, M. S., Mikolajczyk, S. D., Finlay, J. A., and Tindall, D. J. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology, 49: 487-493, 1997.
10. Young, C. Y., Seay, T., Hogen, K., Charlesworth, M. C., Roche, P. C., Klee, G. G., and Tindall, D. J. Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer. Prostate, 7 (Suppl.): 17-24, 1996.
11. Riegman, P. H., Vlietstra, R. J., van-der-Korput, J. A., Brinkmann, A. O., and Trapman, J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol., 5: 1921-1930, 1991.
12. Pang, S., Taneja, S., Dardashti, K., Cohan, P., Kaboo, R., Sokoloff, M., Tso, C. L., deKernion, J. B., and Belldegrun, A. S. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum. Gene Ther., 6: 1417-1426, 1995.
13. Schuur, E. R., Henderson, G. A., Kmetec, L. A., Miller, J. D., Lamparski, H. G., and Henderson, D. R. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem., 271: 7043-7051, 1996.
14. Dranoff, G. Cancer gene therapy: connecting basic research with clinical inquiry. J. Clin. Oncol., 16: 2548-2556, 1998.
15. Vile, R. G. Gene therapy. Curr. Biol., 8: R73-R75, 1998.
16. Riegman, P. H., Vlietstra, R. J., van der Korput, J. A., Romijn, J. C., and Trapman, J. Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem. Biophys. Res. Commun., 159: 95-102, 1989.
17. Miller, A. D., and Rosman, G. J. Improved retroviral vectors for gene transfer and expression. Biotechniques, 7: 980-982, 1998.
18. Gilligan, M., Knox, P., Weedon, S., Barton, R., Searle, P., Kerr, D. J., and Young, L. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Ther., 5: 965-974, 1998.
19. Mautner, V. Methods for growth and purification of enteric adenovirus type 40. In: W. Wold (ed.), Adenovirus Methods and Protocols, pp. 283-293, New Jersey: Humana Press, 1998.
20. Maniatis, T., Fritsch, E. F., and Sambrook, J. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
21. McNeish, I., Green, N., Gilligan, M., Ford, M., Mautner, V., Young, L., Kerr, D. J., and Searle, P. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther., 5: 1061-1069, 1998.
22. Green, N. K., Youngs, D. J., Neoptolemos, J. P., Friedlos, F., Knox, R. J., Springer, C. J., Anlezark, G. M., Michael, N. P., Melton, R. G., Ford, M. J., Young, L. S., Kerr, D. J., and Searle, P. F. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther., 4: 229-238, 1997.
23. Tursz, T., Cesne, A. L., Baldeyrou, P., Gautier, E., Opolon, P., Schatz, C., Pavirani, A., Courtney, M., Lamy, D., Ragot, T., Saulnier, P., Andremont, A., Monier, R., Perricaudet, M., and Le Chevalier, T. Phase I study of a recombinant adenovinis-mediated gene transfer in lung cancer patients. J. Natl. Cancer Inst., 88: 1857-1863, 1996.
24. Gahery-Segard, H., Molinier-Frenkel, V., Le Boulaire, C., Saulnier, P., Opolon, P., Lengagne, R., Gautier, E., Le Cesne, A., Zitvogel, L., Venet, A., Schatz, C., Courtney, M., Le Chevalier, T., Tursz, T., Guillet, J. G., and Farace. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J. Clin. Invest., 100: 2218-2226, 1997.
25. Scardino, P. T., Adler, H. L., Herman, J. R., Woo, S. L. C., Aguilar-Cordova, E., Timme, T. L., and Thompson, T. C. Herpes simplex virus-thymidine kinase (HSV-tk) mediated gene therapy is safe and active against locally recurrent prostate cancer after irradiation therapy. Proceedings of ASCO. 17: 1998.
26. Sterman, D. H., Treat, J., Litzky, L. A., Amin, K. M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J. M., Albelda, S. M., and Kaiser, L. R. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther., 9: 1083-1092, 1998.